CD8A and B-cell chronic lymphocytic leukemia: In addition, in chronic lymphocytic leukemia (CLL) and myeloid dysplastic syndrome (MDS) patients with impaired humoral responses, mRNA vaccines have the potential to elicit long-lasting CD8+ T-cell-mediated immunity (20).